Skip to content

Frontlight ResearchEarly access

Trial site

Vall d'Hebron University Hospital

Barcelona, 08023, SpainNot linked to an institution yet

27running trials
9closed trials

The trials here

What the 36 trials at this site are about, from their registry records.

Conditions: Lung cancer6 trials
Stroke5 trials
Pancreatic cancer4 trials
Liver and biliary tract cancer3 trials
Migraine3 trials
Atrial fibrillation2 trials
Colorectal cancer2 trials
Fatty liver disease (MASLD/MASH)2 trials
Heart failure2 trials
Obesity2 trials
Acute myeloid leukaemia1 trial
Antiphospholipid syndrome1 trial
and 21 more
Phase: Phase 35 trials
Phase 1/24 trials
Phase 24 trials
Phase 11 trial
Phase 2/31 trial
Status: Recruiting15 trials
Active, not recruiting8 trials
Completed8 trials
Not yet recruiting4 trials
Terminated1 trial
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute4 trials
ETOP IBCSG Partners Foundation2 trials
Advesya SAS1 trial
AgNovos Healthcare, LLC1 trial
Alentis Therapeutics AG1 trial
and 27 more

Running trials

Not yet recruiting
Migraine and Endometriosis: The FEMININE Study
NCT07519343· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Headache Unit
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source
Contact: Susana Maria Cedres Perez, MD
Recruiting
ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure
NCT07484009· Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal· Source
Contact: Toni Soriano Colomé, MD, PhD
Not yet recruiting
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
NCT06281847· Phase 1/2· Advesya SAS· Source
Contact: Pere Barba
Recruiting
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
NCT06887803· Phase 1/2· iOnctura· Source
Contact: Maria Laura Fox, MD
Recruiting
Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke
NCT07174505· Anaconda Biomed S.L.· Source
Contact: Manuel Requena, MD
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734· Phase 1/2· Alentis Therapeutics AG· Source
Contact: Principal Investigator
Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515· Reprieve Cardiovascular, Inc· Source
Contact: Annemarie Forrest
Not yet recruiting
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
NCT06929182· Central Hospital, Nancy, France· Source
Contact: Jose Pardos-Gea, MD,PhD
Recruiting
Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy
NCT07713537· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Jorge Pagola Perez, MD, PhD.
Recruiting
Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis
NCT06873308· IRCCS Sacro Cuore Don Calabria di Negrar· Source
Contact: Fernando Salvador Velez
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT05976685· Insel Gruppe AG, University Hospital Bern· Source
Contact: Jorge Pagola
Recruiting
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Patricia Pozo-Rosich, MD, PhD
Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
NCT06408441· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Source
Contact: Carlo M. Cicala
Recruiting
Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification
NCT06674772· Hospital Universitari Vall d'Hebron Research Institute· Source
Contact: Patricia Pozo-Rosich, MD, PhD
Recruiting
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
NCT04701684· Philips Clinical & Medical Affairs Global· Source
Contact: Marc Ribo
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350· AgNovos Healthcare, LLC· Source
Contact: RESTORE Study
Recruiting
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
NCT07717437· Maastricht University Medical Center· Source
Contact: Laura Vidal Piñeiro, Dr.
Active, not recruiting
A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
NCT04253015· RECORDATI GROUP· Source
Active, not recruiting
LITMUS Imaging Study
NCT05479721· University of Oxford· Source
Active, not recruiting
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
NCT03049189· Phase 3· ITM Solucin GmbH· Source
Active, not recruiting
Validation and Standardization of Paramagnetic Rim Lesion (PRL) Identification in Multiple Sclerosis Across MAGNIMS Centers
NCT07705581· IRCCS San Raffaele· Source
Active, not recruiting
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02489006· Phase 2· University Health Network, Toronto· Source
Recruiting
The European NAFLD Registry
NCT04442334· Newcastle University· Source
Contact: Salva Augustin, MD
Active, not recruiting
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436· Phase 3· UNICANCER· Source
Active, not recruiting
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT01924819· Phase 2/3· Australasian Gastro-Intestinal Trials Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke
NCT06634303· Hybernia Medical· Source
Completed
Narrow Band Imaging Versus Artificial Intelligence for Colonic Surveillance in Inflammatory Bowel Disease
NCT07694362· Vall d'Hebron Institute Research· Source
Completed
OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.
NCT05844566· Imperial College London· Source
Terminated
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
NCT04908956· Phase 2· ETOP IBCSG Partners Foundation· Source
Completed
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
NCT04889183· Phase 3· University Medical Center Groningen· Source
Completed
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
NCT04799249· Phase 3· G1 Therapeutics, Inc.· Source
Completed
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
NCT04245085· Phase 2· ETOP IBCSG Partners Foundation· Source
Completed
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NCT03377491· Phase 3· NovoCure Ltd.· Source
Completed
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
NCT03516214· Phase 1· University of Cologne· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error

Vall d'Hebron University Hospital: trial site – Frontlight Research